Antares pharma inc.

Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is an emerging, specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies.

Antares pharma inc. Things To Know About Antares pharma inc.

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Pipeline :: Antares Pharma. Halozyme has completed its acquistion of Antares Pharma, creating a leading drug delivery business. View details here.The FDA has approved the oral drug estosterone undecanoate (Tlando; Antares Pharma, Inc) for testosterone replacement therapy (TRT) for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult patients. “The FDA approval of Tlando brings to market an oral formulation of testosterone that we believe …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...

Oct 1, 2018 · Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery ...

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX: AIS - News) today announced the appointment of Paul K. Wotton, Ph.D., as the Company’s President and Chief Executive Officer effective immediately. Dr. Wotton previously served as President and Chief Operating Officer. Concurrently, Jack E. Stover has resigned as both …Delaware . 1-32302 . 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...About us. About Antares Antares Pharma is a specialty pharmaceutical company that combines drug development expertise with proprietary delivery technology to deliver safe and effective...Delaware . 1-32302 . 41-1350192 (State or Other Jurisdiction. of Incorporation) (Commission. File Number) (I.R.S. Employer. Identification No.) 100 Princeton South ...View Antares Pharma, Inc. Marketing Contacts, Executives, Media Spend, Marketing Technologies and Brands. Open doors with marketers, their agencies and the ...Halozyme, Inc. is offering a free disposal program for your used auto-injectors. We will send you a complete disposal kit by mail. ... describes the terms and conditions applicable to your use of any and all of Antares Pharma, Inc.’s and/or its affiliates (collectively “Antares”) or Antares co-branded websites. If you do not agree to …

A company with a name that ends in “inc.” is incorporated, giving its owners, officers and investors specific legal advantages. Essentially, these key people in the business have no personal liability in the event that the business fails or...

Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. The Company develops, manufactures and commercializes, for itself or with partners, novel therapeutic …

Oct 18, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. ANTARES PHARMA, INC. (Exact name of registrant specified in its charter) _____ Delaware: 001-32302: 41-1350192 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 100 Princeton South, Suite 300, Ewing, NJ ...Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...SAN DIEGO and EWING, N.J., April 13, 2022 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") and Antares Pharma, Inc. (NASDAQ: ATRS) ("Antares") today announced that the...23. 5. 2022 ...Apple Inc. employs 115,000 employees worldwide, with most being in the U.S. Many other jobs are attributable to Apple, including 627,000 created to support the iOS ecosystem. The company has 478 retail locations worldwide.

On April 12, 2022, Halozyme Therapeutics, Inc. (the “Buyer”, “Halozyme”, “Parent”, “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Antares Pharma, Inc., a Delaware corporation (the “Seller” or “Antares”), and Atlas Merger Sub, Inc. (“Merger Sub” or the “Acquirer”), a Delaware corporation and wholly owned …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...Get the latest Antares Pharma Inc. (ATRS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Get the latest Antares Pharma Inc. (ATRS) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.Abstract. Medi-Ject Corporation (now Antares Pharma, Inc.) has been providing delivery devices for the needle-free administration of insulin for over 25 years. This study was one of the final steps in the development and premarket evaluation of Medi-Ject's newest needle-free system, the Medi-Jector Vision. This study was conducted to evaluate ... Apr 13, 2022 · Halozyme Therapeutics Inc. agreed to a nearly $1 billion deal to buy specialty pharmaceutical company Antares Pharma Inc. in a move that will deepen its focus on drug delivery. Halozyme on ...

Antares Pharma, Inc. 2020 Q3 - Results - Earnings Call Presentation SA Transcripts Thu, Nov. 05, 2020 Halozyme Therapeutics, Inc. (HALO) CEO Helen Torley on Q3 2020 Results - Earnings Call Transcript

Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The companys injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA ...Halozyme Inc. is an Equal Employment Opportunity (EEO) employer. It is the policy of the Company to provide equal employment opportunities to all qualified ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...SEC Filings. Next. Showing 1 to 50 of 619. Date. Title. Type. 2023-02-10. SC 13G/A [Amend] - Statement of acquisition of be. SC 13G/A.27. 6. 2016 ... Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) and Antares Pharma, Inc. (NASDAQ:ATRS) today announced the launch of the generic ...Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in ...

EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that …

Antares Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery ...

Halozyme Inc. is an Equal Employment Opportunity (EEO) employer. It is the policy of the Company to provide equal employment opportunities to all qualified applicants without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, age, protected veteran or disabled status, or genetic information. SALT LAKE CITY - Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced it has entered into an exclusive licensing agreement with Antares Pharma, Inc. to commercialize TLANDO in the United States.TLANDO is an oral testosterone product for …Mar 30, 2022 · Antares Pharma announces FDA approval of Tlando™, an oral treatment for testosterone replacement therapy. News release. Antares Pharma Inc. Accessed March 29, 2022. Dec 20, 2011 · Tiberend Strategic Advisors, Inc. Jason Rando. (212) 827-0020. [email protected]. Share. Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America. SEC Filings. Next. Showing 1 to 50 of 619. Date. Title. Type. 2023-02-10. SC 13G/A [Amend] - Statement of acquisition of be. SC 13G/A.Antares Pharma, Inc. (NASDAQ:ATRS) issued its quarterly earnings data on Thursday, November, 4th. The specialty pharmaceutical company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The specialty pharmaceutical company earned $48.19 million during the quarter, compared to the consensus estimate …Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ...Antares Pharma, Inc. (Exact Name of Registrant Specified in Charter) Delaware (State or Other. Jurisdiction of. Incorporation) 1-32302 (Commission File. Number) 41-1350192 (I.R.S. Employer. Identification No.) 250 Phillips Blvd., Suite 290, Ewing, NJ . 08618 (Address of Principal Executive Offices) (Zip Code) Registrant’s telephone number, including area …Tiberend Strategic Advisors, Inc. Jason Rando. (212) 827-0020. [email protected]. Share. Antares Pharma, Inc. (NYSE Amex: AIS) today announced that it has licensed to Pfizer Inc.’s Consumer Healthcare Business Unit one of its drug delivery technologies to develop an undisclosed product on an exclusive basis for North America.

Halozyme will pay $5.60 for each share of Antares Pharma, a premium of 49.7% to the company's last closing price. Shares of Antares surged 48% in premarket trading.0. (Reuters) -Halozyme Therapeutics Inc is bolstering its drug delivery platform with a $960 million all-cash deal for specialty pharmaceutical company Antares Pharma Inc, the companies said on Wednesday. San Diego-based Halozyme offers delivery technology that enables high volumes of a drug to be injected under the skin, potentially …Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas.Instagram:https://instagram. workers compensation insurance companies nytop 10 stocks to buy nownok'rover stock Jan 26, 2016 · Antares Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. avyaqhome building stocks Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in ... spy annual returns Antares Pharma, Inc. (“Antares,” “we,” “our,” “us” or the “Company”) is an emerging, specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies.Oct 18, 2021 · Antares Pharma, Inc. is a specialty pharmaceutical company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug ... ... Antares Pharma, Inc.'s and/or its affiliates (collectively “Antares”) or Antares co-branded websites. If you do not agree to the terms and conditions of ...